UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Radiolabeled Peptides for Cancer Imaging and Therapy: From Bench-to-Bedside

Chimia, 2021-06, Vol.75 (6), p.500

2021

Volltextzugriff (PDF)

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [ 177 Lu]Lu-OPS201 Compared to the Agonist [ 177 Lu]Lu-DOTA-TATE

Pharmaceuticals (Basel, Switzerland), 2021-12, Vol.14 (12), p.1265

2021

Volltextzugriff (PDF)

Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists

Pharmaceuticals (Basel, Switzerland), 2023-04, Vol.16 (5), p.674

2023

Volltextzugriff (PDF)

CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (123/131I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors

Journal of translational medicine, 2023-09, Vol.21 (1), p.1-604, Article 604

2023

Volltextzugriff (PDF)

Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT

Journal of Nuclear Medicine, 2010-07, Vol.51 (7), p.1059-1067

2010

Volltextzugriff (PDF)

Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [177Lu]Lu-Satoreotide Tetraxetan and the Agonist [177Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST2-Positive Tumours

Pharmaceuticals (Basel, Switzerland), 2022-08, Vol.15 (9), p.1085

2022

Volltextzugriff (PDF)

Evaluation of a New 177Lu-Labeled Somatostatin Analog for the Treatment of Tumors Expressing Somatostatin Receptor Subtypes 2 and 5

Molecules (Basel, Switzerland), 2020-09, Vol.25 (18), p.4155

2020

Volltextzugriff (PDF)

Approaches to Improve the Pharmacokinetics of Radiolabeled Glucagon-Like Peptide-1 Receptor Ligands Using Antagonistic Tracers

Journal of Nuclear Medicine, 2016-08, Vol.57 (8), p.1282-1288

2016

Volltextzugriff (PDF)

A new 68Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting

EJNMMI research, 2020-08, Vol.10 (1), p.90-90, Article 90

2020

Volltextzugriff (PDF)

In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study

EJNMMI research, 2024-04, Vol.14 (1), p.37-37, Article 37

2024

Volltextzugriff (PDF)

SPECT Imaging of SST2-Expressing Tumors with 99mTc-Based Somatostatin Receptor Antagonists: The Role of Tetraamine, HYNIC, and Spacers

Pharmaceuticals (Basel, Switzerland), 2021-03, Vol.14 (4), p.300

2021

Volltextzugriff (PDF)

Copper-61 is an advantageous alternative to gallium-68 for PET imaging of somatostatin receptor-expressing tumors: a head-to-head comparative preclinical study

Frontiers in nuclear medicine, 2024, Vol.4, p.1481343

2024

Volltextzugriff (PDF)

Selection of the First 99mTc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation—Preclinical Assessment of Two Optimized Candidates

Pharmaceuticals (Basel, Switzerland), 2020-12, Vol.14 (1), p.19

2020

Volltextzugriff (PDF)

Design and development of the theranostic pair 177 Lu-OPS201/ 68 Ga-OPS202 for targeting somatostatin receptor expressing tumors

Journal of labelled compounds & radiopharmaceuticals, 2019-08, Vol.62 (10), p.635-645

2019

Volltextzugriff (PDF)

Radiolabeled Somatostatin Analogs-A Continuously Evolving Class of Radiopharmaceuticals

Cancers, 2022-02, Vol.14 (5), p.1172

2022

Volltextzugriff (PDF)

Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides

European journal of nuclear medicine and molecular imaging, 2023-08, Vol.50 (10), p.3050-3061

2023

Volltextzugriff (PDF)

Bombesin-Targeted PET of Prostate Cancer

Journal of Nuclear Medicine, 2016-10, Vol.57 (Suppl 3), p.67S-72S

2016

Volltextzugriff (PDF)

Radiolabeled peptides and their expanding role in clinical imaging and targeted cancer therapy

Journal of peptide science, 2024-10, Vol.30 (10), p.e3607-n/a

2024

Volltextzugriff (PDF)

PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference

The Journal of nuclear medicine (1978), 2011-07, Vol.52 (7), p.1110-1118

2011

Volltextzugriff (PDF)

Development of a New Class of CXCR4-Targeting Radioligands Based on the Endogenous Antagonist EPI-X4 for Oncological Applications

Journal of medicinal chemistry, 2023-07, Vol.66 (13), p.8484-8497

2023

Volltextzugriff (PDF)

Hybrid Bombesin Analogues: Combining an Agonist and an Antagonist in Defined Distances for Optimized Tumor Targeting

Journal of the American Chemical Society, 2013-11, Vol.135 (45), p.16793-16796

2013

Volltextzugriff (PDF)

P-69 - New bicyclic somatostatin receptor agonists for imaging and therapy of neuroendocrine neoplasia

Nuclear medicine and biology, 2022-11, Vol.114-115, p.S66-S67

2022

Volltextzugriff (PDF)

New bicyclic somatostatin receptor agonists for imaging and therapy of neuroendocrine neoplasia

Nuclear medicine and biology, 2022-11, Vol.114-115, p.S66-S67

2022

Volltextzugriff (PDF)

Design and development of the theranostic pair 177Lu‐OPS201/68Ga‐OPS202 for targeting somatostatin receptor expressing tumors

Journal of labelled compounds & radiopharmaceuticals, 2019-08, Vol.62 (10), p.635-645

2019

Volltextzugriff (PDF)

Radiolabeled Bombesin Analogs

Cancers, 2021-11, Vol.13 (22), p.5766

2021

Volltextzugriff (PDF)

1 – 25 von 73

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(73)
Mit Volltextzugriff
(69)

Publikationsform

Artikel
(73)

Sprache

Englisch
(73)

Erscheinungsjahr

n.n

Thema

Science & Technology
(37)
Life Sciences & Biomedicine
(33)
Humans
(29)
Animals
(25)
Tumors
(21)
Mice
(19)
Peptides
(19)
Cell Line, Tumor
(14)
Nuclear Medicine
(13)
Oncology
(13)
Radiology, Nuclear Medicine & Medical Imaging
(12)
Tissue Distribution
(12)
Male
(11)
Female
(10)
Imaging
(10)
Medicine
(10)
Medicine & Public Health
(10)
Pharmacology & Pharmacy
(10)
Prostate Cancer
(10)
Radiology
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Radiolabeled Peptides for Cancer Imaging and Therapy: From Bench-to-Bedside

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [ 177 Lu]Lu-OPS201 Compared to the Agonist [ 177 Lu]Lu-DOTA-TATE

Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists

CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (123/131I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors

Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT

Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [177Lu]Lu-Satoreotide Tetraxetan and the Agonist [177Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST2-Positive Tumours

Evaluation of a New 177Lu-Labeled Somatostatin Analog for the Treatment of Tumors Expressing Somatostatin Receptor Subtypes 2 and 5

Approaches to Improve the Pharmacokinetics of Radiolabeled Glucagon-Like Peptide-1 Receptor Ligands Using Antagonistic Tracers

A new 68Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting

In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study

SPECT Imaging of SST2-Expressing Tumors with 99mTc-Based Somatostatin Receptor Antagonists: The Role of Tetraamine, HYNIC, and Spacers

Copper-61 is an advantageous alternative to gallium-68 for PET imaging of somatostatin receptor-expressing tumors: a head-to-head comparative preclinical study

Selection of the First 99mTc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation—Preclinical Assessment of Two Optimized Candidates

Design and development of the theranostic pair 177 Lu-OPS201/ 68 Ga-OPS202 for targeting somatostatin receptor expressing tumors

Radiolabeled Somatostatin Analogs-A Continuously Evolving Class of Radiopharmaceuticals

Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides

Bombesin-Targeted PET of Prostate Cancer

Radiolabeled peptides and their expanding role in clinical imaging and targeted cancer therapy

PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference

Development of a New Class of CXCR4-Targeting Radioligands Based on the Endogenous Antagonist EPI-X4 for Oncological Applications

Hybrid Bombesin Analogues: Combining an Agonist and an Antagonist in Defined Distances for Optimized Tumor Targeting

P-69 - New bicyclic somatostatin receptor agonists for imaging and therapy of neuroendocrine neoplasia

New bicyclic somatostatin receptor agonists for imaging and therapy of neuroendocrine neoplasia

Design and development of the theranostic pair 177Lu‐OPS201/68Ga‐OPS202 for targeting somatostatin receptor expressing tumors

Radiolabeled Bombesin Analogs

Suchergebnisse filtern